Itraconazole Reverts ABCB1-Mediated Docetaxel Resistance in Prostate Cancer

Docetaxel (DTX) was the first chemotherapeutic agent to demonstrate significant efficacy in the treatment of men with metastatic castration-resistant prostate cancer. However, response to DTX is generally short-lived, and relapse eventually occurs due to emergence of drug-resistance. We previously e...

Descripción completa

Detalles Bibliográficos
Autores principales: Lima, Thiago S., Souza, Luciano O., Iglesias-Gato, Diego, Elversang, Johanna, Jørgensen, Flemming Steen, Kallunki, Tuula, Røder, Martin A., Brasso, Klaus, Moreira, José M.A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9203833/
https://www.ncbi.nlm.nih.gov/pubmed/35721223
http://dx.doi.org/10.3389/fphar.2022.869461

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9203833/
https://www.ncbi.nlm.nih.gov/pubmed/35721223
http://dx.doi.org/10.3389/fphar.2022.869461

Ejemplares similares